{
  "docId": "019de070-3b27-7318-9c92-a5817b78bd41",
  "docSlug": "ce86c4a3bf509aea21f24e2159890cb6",
  "documentTitle": "BioNTech | Results Presentation Deck | 28 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 28,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-3b27-7318-9c92-a5817b78bd41/10",
  "deckHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41",
  "deckJsonHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41.json",
  "deckAnchorHref": "/decks/019de070-3b27-7318-9c92-a5817b78bd41#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.7,
        "x": 0.24,
        "y": 0.6
      },
      "kind": "list",
      "text": "Signed strategic collaboration to jointly conduct randomized Phase 2 trial with BNT111 and Libtayo® (cemiplimab anti-PD-1 therapy). Targeting patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma. Companies to share development costs equally and keep full commercial rights to own programs. Plan to initiate potentially registrational Phase 2 trial by the end of 2020 – more details on anticipated trial design to be released in Q3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cae5ba2-3224-42dd-813c-b717a57af553",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.7,
        "x": 0.24,
        "y": 0.23
      },
      "kind": "list",
      "text": "Phase 1 trial data in CPI-experienced patients in monotherapy and in combination with anti-PD1 previously reported in July 2020 and published in Nature. All patients showed tumor associated antigen (TAA) specific T cell responses with In vitro stimulation, and > 75% of patients showed immune responses against ≥ 1 TAA on an ex vivo basis. T cells responses ramped up over 4-8 weeks and increased or remained stable up to over one year with monthly maintenance therapy. Reported durable clinical responses in monotherapy and in combination with anti-PD1 accompanied by high magnitude CD4+ and CD8+ response",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "882bcfa0-ea27-4b2b-9a93-a06250a2cbb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.18,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "Regeneron strategic collaboration and planned Phase 2 trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34326990-e2cc-4cab-865f-65456ebf7245",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.18,
        "x": 0.05,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Ongoing Phase 1 trial in Advanced Melanoma published in Nature",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd1489d9-043e-4198-9445-71013a8882e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT111 Fixvac Melanoma: Planning to initiate randomized phase 2 trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27a36abc-8f81-4567-a3f8-14abae565c8c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "27d12b44-a946-4b6a-9bc1-47cbe3003b84",
      "evidence": "Planning to initiate randomized phase 2 trial",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 10,
      "from": 6,
      "beatId": "d225e240-012c-43ec-9ad8-8849e22c98f8",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights the potential for multiple blockbuster opportunities and the need for innovative solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 6,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "558811c9-2680-40b0-851c-c38adb20b5e2",
      "evidence": "The presentation highlights the company's focus on immunotherapy and COVID-19 vaccine development",
      "position": 0,
      "objective": "What are the key areas of focus for BioNTech's pipeline?",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}